MX350293B - Modificacion dirigida al sitio del factor viii. - Google Patents
Modificacion dirigida al sitio del factor viii.Info
- Publication number
- MX350293B MX350293B MX2014005051A MX2014005051A MX350293B MX 350293 B MX350293 B MX 350293B MX 2014005051 A MX2014005051 A MX 2014005051A MX 2014005051 A MX2014005051 A MX 2014005051A MX 350293 B MX350293 B MX 350293B
- Authority
- MX
- Mexico
- Prior art keywords
- site
- fviii
- directed modification
- polyethylene glycol
- factor viii
- Prior art date
Links
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 229960000301 factor viii Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 230000002947 procoagulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente invención se refiere a un conjugado que tiene actividad procoagulante de factor VIII que comprende un polipéptido de factor VIII funcional unido covalentemente a uno o más polímeros biocompatibles para usarse en el tratamiento de la hemofilia en un paciente que tiene anticuerpos inhibidores de factor VIII, en donde el polímero biocompatible está unido covalentemente al polipéptido de factor VIII funcional en un sitio que es o está dentro de 20 Angstrom de un sitio de unión para los anticuerpos inhibidores de factor VIII.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62727704P | 2004-11-12 | 2004-11-12 | |
PCT/US2005/041205 WO2006053299A2 (en) | 2004-11-12 | 2005-11-14 | Site-directed modification of fviii |
Publications (1)
Publication Number | Publication Date |
---|---|
MX350293B true MX350293B (es) | 2017-09-04 |
Family
ID=36337298
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007005466A MX2007005466A (es) | 2004-11-12 | 2005-11-14 | Modificacion dirigida al sitio del factor viii. |
MX2014005051A MX350293B (es) | 2004-11-12 | 2005-11-14 | Modificacion dirigida al sitio del factor viii. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007005466A MX2007005466A (es) | 2004-11-12 | 2005-11-14 | Modificacion dirigida al sitio del factor viii. |
Country Status (32)
Country | Link |
---|---|
US (4) | US7632921B2 (es) |
EP (9) | EP3153181A1 (es) |
JP (5) | JP2008524117A (es) |
KR (7) | KR20180110192A (es) |
CN (6) | CN103102406B (es) |
AU (1) | AU2005304622B2 (es) |
BR (2) | BRPI0517795B8 (es) |
CA (1) | CA2586379C (es) |
CY (3) | CY1119292T1 (es) |
DK (3) | DK2371856T3 (es) |
ES (4) | ES2930159T3 (es) |
FR (1) | FR19C1031I2 (es) |
HK (3) | HK1117875A1 (es) |
HN (1) | HN2007015683A (es) |
HR (2) | HRP20180481B1 (es) |
HU (5) | HUE033776T2 (es) |
IL (3) | IL182903A (es) |
LT (5) | LT3130601T (es) |
LU (1) | LUC00118I2 (es) |
MA (1) | MA29663B1 (es) |
MX (2) | MX2007005466A (es) |
NL (1) | NL300989I2 (es) |
NO (3) | NO20210454A1 (es) |
NZ (1) | NZ555032A (es) |
PH (2) | PH12014500352A1 (es) |
PL (3) | PL1824988T3 (es) |
PT (4) | PT1824988T (es) |
RU (1) | RU2423380C2 (es) |
SI (4) | SI3130601T1 (es) |
UA (1) | UA95225C2 (es) |
WO (1) | WO2006053299A2 (es) |
ZA (1) | ZA200703696B (es) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
KR101100059B1 (ko) * | 2004-06-30 | 2011-12-29 | 넥타르 테라퓨틱스 | 중합체인자 ix 부분의 접합체 |
EP1771066A2 (en) | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
ES2572779T3 (es) | 2004-10-29 | 2016-06-02 | Ratiopharm Gmbh | Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF) |
PL1824988T3 (pl) | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
EP2386571B1 (en) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
EP2213733A3 (en) * | 2006-05-24 | 2010-12-29 | Novo Nordisk Health Care AG | Factor IX analogues having prolonged in vivo half life |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
BRPI0720282B8 (pt) | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
CA2682897C (en) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
US8173597B2 (en) * | 2007-11-09 | 2012-05-08 | Baxter International Inc. | Modified recombinant factor VIII and von Willebrand factor and methods of use |
US20130189239A1 (en) * | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
CN104059155A (zh) | 2008-05-16 | 2014-09-24 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
US20110286988A1 (en) * | 2008-06-04 | 2011-11-24 | Bayer Healthcare Llc | FVIII Muteins for Treatment of Von Willebrand Disease |
ES2531464T3 (es) | 2008-06-24 | 2015-03-16 | Csl Behring Gmbh | Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada |
WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
WO2010045568A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
CA2740793A1 (en) * | 2008-11-03 | 2010-06-03 | Haiyan Jiang | Method for the treatment of hemophilia |
WO2010060081A1 (en) * | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
US20120121613A1 (en) * | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
CN116925238A (zh) | 2009-02-03 | 2023-10-24 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
WO2010102886A1 (en) * | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
CN102369209B (zh) * | 2009-03-20 | 2015-06-10 | 韩美科学株式会社 | 制备特异性位点生理活性多肽结合物的方法 |
WO2010111414A1 (en) * | 2009-03-24 | 2010-09-30 | Bayer Healthcare Llc | Factor viii variants and methods of use |
RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
EP2459226B1 (en) | 2009-07-27 | 2016-06-29 | Lipoxen Technologies Limited | Glycopolysialylation of proteins other than blood coagulation proteins |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
ES2597954T3 (es) | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
CN102741422B (zh) * | 2009-08-24 | 2016-06-08 | 阿穆尼克斯运营公司 | 凝血因子ⅶ组合物及其制备和使用方法 |
CN102791285A (zh) | 2009-12-06 | 2012-11-21 | 比奥根艾迪克依蒙菲利亚公司 | 因子VIII-Fc嵌合多肽和杂交多肽及其使用方法 |
US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
WO2011101242A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
WO2011103531A1 (en) * | 2010-02-21 | 2011-08-25 | Bayer Healthcare Llc | Method for Activation and Conjugation of Biomolecules |
AU2011239434B2 (en) | 2010-04-15 | 2015-04-30 | Kodiak Sciences Inc. | High molecular weight zwitterion-containing polymers |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
WO2012006623A1 (en) * | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
JP5922141B2 (ja) | 2010-11-05 | 2016-05-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 増加した比活性を有する抗血友病第viii因子の新規変異体 |
CN103282045A (zh) * | 2010-12-16 | 2013-09-04 | 诺沃—诺迪斯克有限公司 | 因子viii水溶液 |
ES2800983T3 (es) | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
WO2012166622A1 (en) * | 2011-05-27 | 2012-12-06 | Baxter International Inc. | Therapeutic proteins with increased half-life and methods of preparing same |
WO2012170969A2 (en) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Pro-coagulant compounds and methods of use thereof |
CA2840552A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
EP2729161B1 (en) | 2011-07-08 | 2018-12-19 | Bioverativ Therapeutics Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
KR20140070612A (ko) | 2011-09-23 | 2014-06-10 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第viii因子タンパク質 |
JP6256882B2 (ja) | 2012-02-15 | 2018-01-10 | アムニクス オペレーティング インコーポレイテッド | 第viii因子組成物、ならびに組成物の作製方法および用途 |
EP2666782A1 (en) | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
JP2015521589A (ja) | 2012-06-08 | 2015-07-30 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | プロコアグラント化合物 |
EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
US20150266944A1 (en) | 2012-10-30 | 2015-09-24 | Biogen Idec Ma Inc. | Methods of Using FVIII Polypeptide |
PT3666283T (pt) | 2013-03-15 | 2022-09-13 | Bioverativ Therapeutics Inc | Formulações de polipéptido de fator viii |
CA2899089C (en) | 2013-03-15 | 2021-10-26 | Biogen Ma Inc. | Factor ix polypeptide formulations |
AU2014237111B2 (en) * | 2013-03-15 | 2018-06-21 | Bayer Healthcare Llc | Recombinant factor VIII formulations |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
EP4108254A1 (en) | 2013-08-14 | 2022-12-28 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP3760639A1 (en) | 2013-09-08 | 2021-01-06 | Kodiak Sciences Inc. | Zwitterionic polymer conjugates |
WO2015059121A1 (en) * | 2013-10-22 | 2015-04-30 | Dbv Technologies | Method of treating haemophilia by inducing tolerance to blood factors |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
RU2546297C1 (ru) * | 2013-11-19 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, улучшающее реологические свойства крови |
EP4332839A2 (en) | 2013-12-06 | 2024-03-06 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
KR101908074B1 (ko) * | 2014-01-20 | 2018-10-15 | 옥타파마 아게 | 개선된 FVIII:C/FVIII:Ag의 비를 갖는 인자 VIII의 제조방법 |
EP3102589A1 (en) | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
JP7058940B2 (ja) | 2014-03-24 | 2022-04-25 | バイオベラティブ セラピューティクス インコーポレイテッド | 凍結乾燥第ix因子製剤 |
US11181534B2 (en) * | 2014-04-04 | 2021-11-23 | Bloodworks | Routine laboratory and point-of-care (POC) testing for hemostasis |
CA2945390A1 (en) | 2014-04-10 | 2015-10-15 | Bayer Healthcare Llc | Compounded media powder formulation and method of preparation of liquid medium for cell culture |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
CN106659771B (zh) | 2014-07-02 | 2021-09-24 | 康诺贝林伦瑙有限公司 | 修饰的von Willebrand因子 |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
EP3265483B1 (en) | 2015-03-06 | 2019-12-11 | CSL Behring Lengnau AG | Modified von willebrand factor having improved half-life |
ES2774011T3 (es) | 2015-05-22 | 2020-07-16 | CSL Behring Lengnau AG | Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia |
EP4089109A3 (en) | 2015-05-22 | 2023-03-01 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
SG11201805494WA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
BR112018013861A2 (pt) | 2016-01-07 | 2018-12-18 | Csl Behring Recombinant Facility Ag | polipeptídeo, complexo, composição farmacêutica, métodos para tratar um distúrbio de coagulação sanguínea, para produzir um polipeptídeo e um dímero de um polipeptídeo, para aumentar a meia vida do fator viii e para aumentar a dimerização do dito polipeptídeo, uso de um polipeptídeo, kit farmacêutico, plasmídeo ou vetor, e, célula hospedeira |
US20230151078A1 (en) * | 2016-06-24 | 2023-05-18 | Mogam Instiitute For Biomedical Research | Recombinant single-chain fviii and chemical conjugate thereof |
DK3538134T3 (da) | 2016-11-11 | 2022-02-07 | CSL Behring Lengnau AG | Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse |
AU2017358861B2 (en) | 2016-11-11 | 2022-02-17 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
JP2020504084A (ja) | 2016-11-16 | 2020-02-06 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 赤血球標的化第viii因子およびその使用方法 |
IL266972B2 (en) | 2016-12-02 | 2024-04-01 | Bioverativ Therapeutics Inc | Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors |
BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
MA52630A (fr) | 2018-05-18 | 2021-05-26 | Bioverativ Therapeutics Inc | Procédés de traitement de l'hémophilie a |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021091881A1 (en) * | 2019-11-04 | 2021-05-14 | The Trustees Of Columbia University In The City Of New York | High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof |
CA3159985A1 (en) * | 2019-12-06 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
EP0294910B1 (en) | 1987-06-12 | 1996-09-11 | Immuno Ag | Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
US5171844A (en) | 1987-06-12 | 1992-12-15 | Gist-Brocades N.W. | Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
AU2473388A (en) * | 1987-11-16 | 1989-06-22 | Scripps Clinic And Research Foundation | Treatment of factor viii inhibitors |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
WO1994007510A1 (en) | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
WO1995011987A1 (en) | 1993-10-29 | 1995-05-04 | Incyte Pharmaceuticals, Inc. | Chimeric proteins including protease nexin-1 variants |
IL113010A0 (en) | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
AU691111B2 (en) * | 1995-06-21 | 1998-05-07 | Google Technology Holdings LLC | Method and antenna for providing an omnidirectional pattern |
WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AT403438B (de) | 1996-05-24 | 1998-02-25 | Immuno Ag | Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität |
US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
CA2262994A1 (en) * | 1996-08-02 | 1998-02-12 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
NZ502375A (en) | 1997-07-14 | 2001-11-30 | Bolder Biotechnology Inc | The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family |
CN1113656C (zh) * | 1997-10-17 | 2003-07-09 | 丰收技术股份有限公司 | 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物 |
EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
CA2329768C (en) | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
PT1129186E (pt) | 1998-11-10 | 2007-12-07 | Sanquin Bloedvoorziening | Um polipéptido factor viii com actividade de factor viii-c |
US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
CN1210400C (zh) * | 1999-01-14 | 2005-07-13 | 博尔德生物技术公司 | 制备含游离半胱氨酸残基的蛋白质的方法 |
WO2000071714A2 (en) | 1999-05-24 | 2000-11-30 | The American National Red Cross | Methods of reducing factor viii clearance and compositions therefor |
DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
PL206105B1 (pl) | 2000-09-19 | 2010-07-30 | Emory Universityemory University | Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej |
WO2002060951A2 (en) | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
EP1373493B1 (en) * | 2001-03-22 | 2013-07-31 | Novo Nordisk Health Care AG | Coagulation factor vii derivative |
WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
WO2002098454A2 (en) | 2001-05-31 | 2002-12-12 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
US7205278B2 (en) | 2001-06-14 | 2007-04-17 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
ES2319745T3 (es) | 2001-10-05 | 2009-05-12 | Expression Therapeutics, Llc | Secuencias de acidos nucleicos y aminoacidos que codifican polipeptidos de factor viii de alto nivel de expresion, y metodos de uso. |
CN1646564A (zh) | 2002-04-18 | 2005-07-27 | 默克专利有限公司 | 修饰的因子ⅷ |
US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
US7432330B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
CA2509260C (en) | 2002-12-31 | 2012-10-02 | Nektar Therapeutics Al, Corporation | Maleamic acid polymer derivatives and their bioconjugates |
DE602004029646D1 (en) | 2003-01-06 | 2010-12-02 | Nektar Therapeutics San Carlos | Thiolselektive wasserlösliche polymerderivate |
SI1596887T1 (sl) * | 2003-02-26 | 2022-05-31 | Nektar Therapeutics | Konjugati polimer-del faktorja VIII |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180054A1 (en) * | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
BRPI0411160A (pt) * | 2003-05-12 | 2006-07-11 | Affymax Inc | novos compostos modificados com poli(glicol etilênico) e usos dos mesmos |
ES2725808T3 (es) | 2003-05-23 | 2019-09-27 | Nektar Therapeutics | Derivados de PEG que contienen dos cadenas de PEG |
EP1502921A1 (en) | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
US20050123997A1 (en) | 2003-10-30 | 2005-06-09 | Lollar John S. | Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
EP1699469B1 (en) | 2003-12-03 | 2010-04-07 | University of Rochester | Recombinant factor viii having increased specific activity |
WO2006027111A1 (en) | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
PL1824988T3 (pl) | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
EP1871801A2 (en) | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Blood coagulation fviii analogues |
KR20080108147A (ko) * | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 viii |
US7645860B2 (en) * | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
-
2005
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 PH PH12014500352A patent/PH12014500352A1/en unknown
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Application Discontinuation
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko active IP Right Grant
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko active Protection Beyond IP Right Term
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es active Active
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko active Protection Beyond IP Right Term
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es active Active
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh active Active
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es active Active
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en unknown
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en active Active
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en active Active
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en active Active
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh active Active
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en active Active
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh active Active
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en active Active
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko active IP Right Grant
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Application Discontinuation
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en active Search and Examination
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr active IP Right Grant
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en active Active
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh active Active
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es active Active
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 CA CA2586379A patent/CA2586379C/en active Active
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en active Active
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko active IP Right Grant
-
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-08 HR HRP20070268AA patent/HRP20070268B1/hr active IP Right Grant
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
-
2008
- 2008-07-15 HK HK08107795.4A patent/HK1117875A1/xx unknown
-
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
-
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja active Active
-
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en active Active
- 2013-08-13 HK HK13109463.4A patent/HK1182121A1/xx unknown
-
2014
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja active Active
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
-
2016
- 2016-06-13 HK HK16106727.9A patent/HK1218718A1/zh unknown
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja active Active
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja active Active
-
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
-
2019
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I1/el unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
-
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501613A1 (en) | Site-directed modification of fviii | |
WO2006047419A3 (en) | Heterobifunctional poly(ethylene glycol) and uses thereof | |
DE50306232D1 (de) | Ampholytisches copolymer und dessen verwendung | |
TR200101751T2 (tr) | Poliol-IFN-beta konjugatları | |
NO20031179D0 (no) | Chemokin-reseptorbindende heterocykliske forbindelser | |
EP3406347A3 (en) | Xten conjugate compositions and methods of making same | |
WO2001058493A8 (en) | Conjugates of follicle stimulating hormones | |
WO2006103298A3 (en) | Blood coagulation fviii analogues | |
GEP20074016B (en) | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | |
ATE455561T1 (de) | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden | |
HK1166606A1 (en) | Polymer-based sustained release device | |
BRPI0507680A (pt) | partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas | |
EP1663171A4 (en) | HETEROFUNCTIONAL COPOLYMERS OF GLYCEROL AND POLYETHYLENE GLYCOL, CONJUGATES AND COMPOSITIONS THEREOF | |
CY1116415T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν l-733060 για χρηση στη θεραπευτικη αγωγη καρκινικων ογκων | |
WO2005084303A3 (en) | Interferon-beta polymer conjugates | |
MX2010001955A (es) | Enlazadores polimericos que contienen porciones de disulfuro-piridilo. | |
UA82983C2 (ru) | Полимерные коньюгаты найбластина и способы их использования | |
MY181129A (en) | Site-directed modification of fviii | |
MY151329A (en) | Site-directed modification of fviii | |
MY173864A (en) | Site-directed modification of fviii | |
MX2010007260A (es) | Mezcla de polimeros. | |
DE60313786D1 (de) | Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4 | |
GT200700040A (es) | Modificacion dirigida al sitio del fviii | |
PL1668027T3 (pl) | Cykliczne peptydy działające jako antagoniści Urotensyny-II |